^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gallbladder Cancer

    Related cancers:
    3d
    ERBB2 I655V mutation correlates with efficacy of immunotherapy in gallbladder cancer. (PubMed, World J Surg Oncol)
    The ERBB2 I655V mutation may be associated with improved treatment response to immunotherapy in gallbladder cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • TYK2 (Tyrosine Kinase 2)
    |
    PD-L1 expression • HER-2 overexpression • HER-2 mutation
    |
    Focus V (anlotinib) • AiRuiKa (camrelizumab)
    7d
    Study on the Effectiveness and Safety of Irreversible Electroporation for Treating Hepatocellular Liver Cancer (ChiCTR2600117385)
    P=N/A, N=20, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University
    New trial
    7d
    Efficacy and safety of Gemox-HAIC in combination with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) in the treatment of advanced biliary-derived malignancies: a case series (ChiCTR2600116095)
    P=N/A, N=40, Not yet recruiting, Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University
    New trial
    7d
    A Real-World Study of Precision Treatment for Advanced Cholangiocarcinoma Based on Molecular Subtyping (ChiCTR2500111407)
    P=N/A, N=55, Not yet recruiting, Fuzhou University Affiliated Provincial Hospital; Fuzhou University Affiliated Provincial Hospital
    New trial
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • RET (Ret Proto-Oncogene) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NRG1 (Neuregulin 1) • VEGFA (Vascular endothelial growth factor A) • RNF43 (Ring Finger Protein 43) • TYK2 (Tyrosine Kinase 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • KRAS mutation • EGFR mutation • MSI-H/dMMR • HER-2 overexpression • HER-2 amplification • PIK3CA mutation • BRAF V600 • MET amplification • RET fusion • FGFR2 mutation • PALB2 mutation • FGFR2 fusion • MET mutation • IDH mutation + BRAF V600E • IDH mutation + NTRK fusion
    7d
    The efficacy and safety of immunoradiotherapy plus gemcitabine, apatinib, and PD-L1 monoclonal antibody as first-line treatment for unresectable biliary tract tumors. (ChiCTR2500111695)
    P=N/A, N=33, Completed, Nanjing Drum Tower Hospital; Nanjing Drum Tower Hospital
    New trial
    |
    gemcitabine • AiTan (rivoceranib)
    7d
    NIOFA-02: A Randomized, Open-Label Cohort Study of Adebrelimab Combined with NALIRIFOX or Gemcitabine-Cisplatin (GC) as First-Line Treatment for Locally Advanced or Metastatic Biliary Tract Cancer (ChiCTR2600116738)
    P4, N=102, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University
    New P4 trial
    |
    cisplatin • gemcitabine • 5-fluorouracil • oxaliplatin • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • AiRuiLi (adebrelimab)
    7d
    A single-arm phase II clinical trial of HIPEC in combination with CRS and durvalumab for the treatment of biliary tract tumors with peritoneal metastases (ChiCTR2500115410)
    P4, N=33, Not yet recruiting, The Third Affiliated Hospital of Naval Medical University; The Third Affiliated Hospital of Naval Medical University
    New P4 trial
    |
    Imfinzi (durvalumab)
    7d
    Trastuzumab Combined With Chemotherapy and Leflunomide for HER2-Expressing Unresectable Advanced Biliary Tract Malignancies: An Open-Label, Single-Arm, Phase II Study (ChiCTR2500112844)
    P2, N=53, Not yet recruiting, The Third Affiliated Hospital of Naval Medical University (Shanghai Eastern Hepatobiliary Surgery Hospital); The Third Affiliated Hospital of Naval Me
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification • HER-2 expression • HER-2 underexpression
    |
    Herceptin (trastuzumab) • leflunomide
    7d
    Gemcitabine and Nab-Paclitaxel Combined With Iparomlimab-Tuvorilimab for Advanced Gallbladder Cancer (ChiCTR2600117584)
    P2, N=44, Not yet recruiting, Xinhua Hospital Affiliated to Shanghai Jiaotong University of Medicine; Xinhua Hospital Affiliated to Shanghai Jiaotong University of Medicine
    New P2 trial
    |
    gemcitabine • albumin-bound paclitaxel • Ojemda (tovorafenib) • iparomlimab (QL1604)
    7d
    A Single-Arm, Single-Center, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) for Second-Line or Later Treatment of Advanced or Metastatic Biliary Tract Cancer (ChiCTR2500112219)
    P2, N=31, Not yet recruiting, The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University
    New P2 trial
    |
    Jiataile (sacituzumab tirumotecan)
    7d
    Liposomal Irinotecan Plus 5-FU/LV Compared with Sequential Alternating nab-Paclitaxel Plus S-1 as Second-Line Therapy in Patients with Advanced Biliary Tract Cancer: A Randomized, Open-Label, Prospective Trial (ChiCTR2500111686)
    P2, N=58, Not yet recruiting, Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital
    New P2 trial
    |
    5-fluorouracil • albumin-bound paclitaxel • Teysuno (gimeracil/oteracil/tegafur)
    7d
    Single arm, multi center, open phase Ib/IIa clinical study on the efficacy and safety of JJH201601 liposome for injection in the treatment of advanced pancreatic cancer, biliary tract cancer and hepatocellular carcinoma (ChiCTR2500111729)
    P1/2, N=90, Recruiting, Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University); Jiangsu Province Hospital (The First Affiliated Hospital wi
    New P1/2 trial